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Familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML) is an autosomal 
dominant disorder and is characterized by inherited mild to moderate thrombocytopenia with or without 
impaired platelet function and a lifelong risk of development into hematological malignancies. Although 
inherited RUNX1 mutation is the cause of thrombocytopenia, secondary mutations may have a role in the 
development and progression of hematological malignancies in FPD/AML, as only about 40 % of 
FPD/AML patients develop leukemia with a median age of 33 years. Difficulty in studying FPD/AML 
pathogenesis exists because it is a rare disorder and only approximately 40 pedigrees with FPD/AML have 
been described in the world so far. Thus we conducted a nationwide survey in Japan to collect samples and 
make a diagnosis of patients with familial thrombocytopenia or hematological malignancies and applied a 
high-throughput sequencing strategy to hematological malignancies in FPD/AML, with the aim of 
identifying novel recurrent driver mutations. As a result, 57 pedigrees were extracted and 7 pedigrees with 
germline RUNX1 mutation were diagnosed as having FPD/AML, in which 8 out of 13 patients had 
developed hematological malignancies. There was no significant difference in platelet count or other 
clinical data at diagnosis between FPD/AML patients and non-FPD/AML patients. 
To identify additional genetic alterations, we utilized whole exome sequencing in two patients with 
FPD/AML who had RUNX1_p.Phe303fs mutation and developed myelodysplastic syndrome (MDS, 
patient 1) or myelofibrosis (patient 2) followed by AML. We confirmed 10 and 8 somatically acquired 
nonsynonymous mutations in these patients, respectively. Interestingly, both patients had a somatic 
CDC25C mutation. Therefore, the other individuals with FPD/AML were investigated by deep sequencing 
and subclone strategy to determine the frequency of mutations in CDC25C. As a result, 7 out of 13 
individuals harbored CDC25C mutations (54 %). Surprisingly, 3 mutations were detected in 5 individuals 
without hematological malignancy. Further sequence analysis in 90 sporadic MDS patients and 53 AML 
patients identified only one CDC25C mutation in a MDS patient among 13 MDS patients with RUNX1 
mutation. Next we estimated clonal evolution during leukemic transformation using variant allele 
frequency (VAF) of validated mutations. In patient 1, a founder clone with CDC25C mutation acquired 
COL9A1, FAM22G, and LPP mutations (group 1), and subsequent emergence of GATA2 mutation (group 
2) triggers full-blown leukemia, whereas another subclone defined by CHEK2 and other mutations in 3 
genes (group 3) relatively regressed. Similar hierarchical progression was observed in patient 2. Single cell 
genomic sequencing using genome DNA of 63 bone marrow cells from Subject 20 at the AML phase 
demonstrated that group 1/2 and group 3 mutations were mutually exclusive and thus validated the 
hierarchical model. 
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Among the somatic mutations found in Subject 20 and 21, GATA2 mutation was also identified in Subject 
22. This patient developed AML with multilineage dysplasia, leading to the diagnosis of AML-MRC. 
Remission induction therapies were partially effective and the blast ratio was reduced from 54 % to 5.6 %, 
while dysplastic feature persisted. Allogeneic stem cell transplantation was successfully performed from an 
HLA-matched unrelated donor and complete remission with 100 % donor chimerism was obtained. During 
the treatment, VAF of GATA2 mutation decreased almost in parallel with blast percentage while VAF of 
CDC25C mutation hovered at a high ratio before transplantation, suggesting that GATA2 mutation confers 
leukemia progression in this patient whereas CDC25C mutation is associated with pre-leukemic status. 
We next investigated the functional impact of CDC25C mutation. CDC25C is a phosphatase that prevents 
premature mitosis in response to DNA damage at the G2/M checkpoint, while it is constitutively 
phosphorylated at Ser216 throughout the interphase by c-TAK1. When phosphorylated at Ser216, 
CDC25C binds to 14-3-3 protein, which sequestrates CDC25C in the cytoplasm and inactivates it. Binding 
capacity with c-TAK1 of mutant CDC25C was reduced compared with wild-type, resulting in decreased 
phosphorylation status of CDC25C at Ser216, decreased binding capacity with 14-3-3 protein, and 
accumulation of mutant CDC25C in the nucleus at the G1/S phase. As a result of these characteristics, 
CDC25C mutants led to enhanced mitosis entry which was exaggerated by irradiation. These results 
suggest that CDC25C mutation results in disruption of DNA checkpoint machinery. 
Next we confirmed that FPD/AML-associated RUNX1 mutations (p.Phe303fs and p.Arg174X) induce 
DNA damage through transcriptional suppression of several DNA repair genes, with activation of the 
G2/M check point mechanism. However, we found that introduction of CDC25C mutation resulted in 
enhancement of mitosis entry in spite of DNA damage induced by RUNX1 mutations. 
In conclusion, FPD/AML-associated malignant transformation is formed by stepwise acquisition of 
mutations and clonal selection, which is initiated by a CDC25C mutation in the pre-leukemic phase and 
further driven by additional mutations. The identification of CDC25C as the gene responsible for the 
transformation will facilitate the diagnosis and monitoring of individuals with FPD/AML who are at an 
increased risk of developing life-threatening hematological malignancy. 
